Traduction de «community health protection branch » (Anglais → Français) :

Public Health Branch [ Community Health Protection Branch ]

HPB Communications Division [ HPBCD | Health Protection Branch Communications Division ]

Health Protection Branch Task Force on Food Safety Risk Communication

Community Health Services Branch

Community action programme on toxicology for health protection

health Protection questions in intra-Community trade in fresh meat

With reference to the antimalarial drug mefloquine administered to Canadian Forces bound for Somalia in 1992-93 and the legal framework under which it was available for use and administered: (a) was mefloquine a licensed drug when it was administered to Canadian Forces, if not what was its status, and how was it legally available; (b) were the Canadian Forces participating in the Lariam (mefloquine) Safety Monitoring Study during this period; (c) was the mefloquine administered in accordance with the Lariam Safety Monitoring Study and the Food and Drug Act; (d) who was the “principal investigator” responsible for the Lariam Safety Monitoring Study in the Canadian Forces; (e) who was the Canadian Forces physician responsible to the “prin ...[+++]cipal investigator” of the Lariam Safety Monitoring Study; (f) what was the role of Canadian Forces physician, Dr. Martin Tepper, in the Lariam Safety Monitoring Study; (g) who was responsible for the Lariam Safety Monitoring Study at the Department of Health's Health Protection Branch during this period; (h) what was the role and responsibility of the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drug Act and its regulations in regard to the use of mefloquine by Canadian Forces personnel; (i) when did the Health Protection Branch become aware that mefloquine was being administered to Canadian Forces personnel bound for Somalia; (j) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine to inform the manufacturer of its use; (k) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act to the soldiers who were administered the drug; (l) did the Canadian Forces fulfil their responsibility to the manufacturer under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine and if so how did they do ...

Witnesses: From Health Canada: Denis Gauthier, Assistant Deputy Minister, Information, Analysis and Connectivity Branch; Jerry Lee, Director, Infostructure Systems Management Division, Information, Analysis and Connectivity Branch; Mimi Breton, Executive Director, Hepatitis C Division, Health Promotion and Programs Branch; Catherine Stewart, Director, Policy Development and Coordination Division, Health Promotion and Programs Branch; David Fransen, Director general, Population Health Directorate, Health Promotion and Programs Bran ...[+++]ch; Janet Davies, Director, Strategies and Systems for Health Directorate, Health Promotion and Programs Branch; Joel Weiner, A/Director General, Policy, Planning and Coordination Directorate, Health Protection Branch; Dr. Moe Hussain, A/Director, Branch Planning Bureau, Health Protection Branch; Gérard Séguin, Director, Financial Services, Health Protection Branch; Margaret Hassock, A/Director, Financial Services, Administration Program, Departmental Planning and Financial Administration Corporate Services Branch; Janice L. Pound, Acting Manager, Office of Strategic Planning, Communications and Quality, Therapeutic Products Programme; Paul R. Mayers, Acting Director, Bureau of Microbial Hazards, Food Directorate, Health Protection Branch; Greg Hunter, Director, Information Resource Management Division; Hervé Leblanc, Director, Health Canada.

With reference to the neuro-psychiatric side-effects experienced by those taking the anti-malarial drug mefloquine (Lariam): (a) Of those Canadians administered mefloquine prior to the date of its licensing for general use by the Health Protection Branch in 1993, how many persons committed suicide or attempted to commit suicide and how many of these incidents were associated with alcohol use; (b) Of those Canadians administered mefloquine after the date of its licensing for general u ...[+++]se by the Health Protection Branch in 1993, how many persons committed suicide or attempted to commit suicide and how many of these incidents were associated with alcohol use; (c) Of those members of the Canadian forces who were administered mefloquine since 1992, how many have attempted suicide or committed suicide; in what year; in Canada or abroad and if abroad name the country; (d) Of those members of the Canadian forces who were administered mefloquine since 1992 and attempted suicide or committed suicide, how many of these incidents were associated with alcohol use; (e) Has the Health Protection Branch reviewed the international experience concerning suicides, suicide attempts, and suicidal ideation associated with mefloquine use, and if so when, and what were the results and recommendations of the review, and what steps have been taken to implement the recommendations; (f) Has the Health Protection Branch reviewed the scientific literature with regard suicides, suicide attempts and suicidal ideation associated with mefloquine use and if so when, and what were the results and recommendations of the review and what steps have been taken to implement the recommendations; (g) Has the Health Protection Branch revised the administering instructions for mefloquine to include warnings regarding suicides, attempted suicides, suicidal ideation, or the combination of mefloquine and alcohol and if so when, and what action taken, and if not does it plan to do so and if so when; (h) Ha ...

With regard to the purchase of mefloquine from the manufacturer and the oversight of mefloquine by the Health Protection Branch as mandated by the Food and Drug Act: (a) did the Canadian Forces indicate to the manufacturer on the order form when ordering mefloquine for Somalia that it was for use under the Food and Drug Act's Lariam Safety Monitoring Study; when was the order submitted; and when was the shipment received; (b) was the Health Protection Branch informed by the manufacturer tha ...[+++]t the Canadian Forces had indicated on the order form that the mefloquine was being ordered under the authority of the Lariam Safety Monitoring Study and that this mefloquine was apparently purchased for the Somalia deployment; and when was the Health Protection Branch so informed; (c) did the Health Protection Branch receive from the manufacturer a request to fast track licensing approval for mefloquine (Lariam), and was licensing approval granted prior to the end of the Canadian Forces deployment in Somalia; (d) what was the date the Health Protection Branch received the final results of the Lariam Safety Monitoring Study from the manufacturer, and the date of the receipt by the Health Protection Branch of the last submission of the Safety Monitoring Study's results prior to licensing approval; (e) did the Department of National Defence prepare an advisory note acknowledging that evidence provided to the Somalia Inquiry had mislead the Inquiry as to the status of mefloquine approvals for the mefloquine used in the Somalia deployment; was the advisory note forwarded to the Minister of National Defence; and what action was taken when the Minister was so informed?